Krzysztof Matyszewski
Krzysztof Matyszewski has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Adam Golebiowski
Molecure S.A., Zwirki i Wigury 101, 02-089 Warsaw, Poland
66 shared publications - Agnieszka Napiorkowska-Gromadzka
Laboratory of Protein Structure, International Institute of Molecular and Cell Biology, Warsaw, Poland
66 shared publications - Agnieszka Zagozdzon
Molecure SA, 02-089 Warsaw, Poland
66 shared publications - Anna Cabaj
Molecure S.A., Warsaw, Poland
66 shared publications - Anna Gzik
Molecure S.A., Warsaw, Poland
66 shared publications - Bartlomiej Borek
Molecure S.A., Zwirki i Wigury 101, 02-089 Warsaw, Poland
66 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Crystal structure of OATD-02 bound to hARG1
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 15 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Crystal structure of OATD-02 bound to hARG1
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
In vitro activity; data collection of hARG1 – OATD-02 complex crystal; PK data; HED and MRSD calculations; projected human exposure to OATD-02
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables 1-11 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
In vitro activity; data collection of hARG1 – OATD-02 complex crystal; PK data; HED and MRSD calculations; projected human exposure to OATD-02
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
The immunosuppressive character of ARG1 and ARG2 in the tumor microenvironment (TME)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
The immunosuppressive character of ARG1 and ARG2 in the tumor microenvironment (TME)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Figures 2 - 14 (Synthesis schemes).
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 2 - 14 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Figures 2 - 14 (Synthesis schemes).
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Materials and Methods not included in the main manuscript
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Supplementary Materials and Methods not included in the main manuscript
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Simulated human plasma concentration time profiles of OATD-02
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 23 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Simulated human plasma concentration time profiles of OATD-02
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Allometric scaling of human plasma clearance (CL-NAS)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 20 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Allometric scaling of human plasma clearance (CL-NAS)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Allometric scaling of human plasma clearance (CL-ROE)
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Allometric scaling of human plasma clearance (CL-ROE)
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Analysis of B16F10 tumor growth in mice treated with OATD-02 in all individuals subjected to the study.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 17 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Analysis of B16F10 tumor growth in mice treated with OATD-02 in all individuals subjected to the study.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Individual body weight changes in animals treated with OATD-02
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 18 from Arginase 1/2 Inhibitor OATD-02: From Discovery to First-in-man Setup in Cancer Immunotherapy
Individual body weight changes in animals treated with OATD-02